Skye Bioscience (SKYE) Director J. Sells $65K of Stock
Skye Bioscience director Andrew J. Schwab sold 33,892 shares of the company on September 16, 2026, continuing a pattern of recent transactions.
Reviewed by automated data checks against the source filing. How we make and check alerts
Schwab Andrew J., Director at Skye Bioscience, Inc. ($SKYE), sold 33,892 shares at an average price of $1.91, worth about $64,733.72, on September 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SKYE is up 5.9% after 1 week, down 8.8% after 1 month and down 8.8% to date (from the $1.70 close on Sep 16, 2026).
SKYE
Skye Bioscience, Inc.
Key Points
- Skye Bioscience director Andrew J. Schwab sold 33,892 shares of the biotech company on September 16, 2026.
- The clinical-stage biotech firm recently traded around $1.58, sitting well below its 52-week high of $13.28.
- Investors will look toward the upcoming earnings release on November 9, 2026, for clinical updates.
Get $SKYE trade alerts by text
We text you when insiders, Congress or big funds trade $SKYE. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Skye Bioscience, Inc. alert may contain errors. Disclosures
Skye Bioscience, Inc. director Andrew J. Schwab sold 33,892 shares of the company on September 16, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the transaction was executed at a price of $1.91 per share, totaling roughly $64,733. The sale was not reported as part of a pre-arranged Rule 10b5-1 trading plan. The stock closed at $1.70 on the day of the transaction.
Inside Schwab's SKYE Trade
The sale by Schwab continues a pattern of insider transactions for the director. Schwab previously sold 375,840 shares on August 20, 2026, following an earlier sale of 231,405 shares on August 22, 2025. These recurring transactions follow a trail of moves by insiders and major stakeholders in the biotechnology firm.
Other Institutional Activity in Skye Bioscience
Other large funds have adjusted their holdings in Skye Bioscience over recent periods. Baker Bros. Advisors grew its holdings by 124,605 shares, ending with 1,575,243 shares worth about $1.09 million. Meanwhile, 5AM Venture Management, LLC held steady with 1,210,220 shares valued at $1.87 million, and Versant Venture Management, LLC maintained its stake of 250,963 shares worth about $388,992. Baker Bros. Advisors, LP kept its position at 196,905 shares valued at $305,202, while Sphera Funds Management Ltd. held 84,866 shares worth about $131,542.
Skye Bioscience, Inc. Stock Down 0.6%
The stock recently traded around $1.58 as of October 16, 2026, sitting below its event-day close and far below its 52-week high of $13.28. The shares hover just above their 52-week low of $1.50.
Recent Earnings
Skye Bioscience reported a trailing twelve-month net loss with an earnings per share of -$10.16. The company carries a return on equity of -233.9%.
Insider Buying and Selling at Skye Bioscience, Inc.
Insiders have recorded multiple transactions over the past year. Schwab and associated entity 5Am Partners Vii sold 231,405 shares in August 2025 and an additional 375,840 shares in August 2026 prior to the September trade.
About Skye Bioscience, Inc.
Skye Bioscience, Inc. is a clinical-stage biotech firm based in San Diego, California. The company focuses on developing molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic conditions.
Bottom Line
Investors are watching for the company's next financial update and clinical progress. The upcoming earnings release is scheduled for November 9, 2026.
Related Filing Alerts
Source: Schwab Andrew J.'s Form 4 filing on $SKYE (Sep 16, 2026). Find the original filing: SKYE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts